Claims for Patent: 9,029,148
✉ Email this page to a colleague
Summary for Patent: 9,029,148
Title: | Methods for the preparation of fibroblasts |
Abstract: | The invention relates to a process for generating fibroblasts, more particularly, to the culturing of fibroblasts in large numbers and of the heterogenic type. The invention is also directed to the use of fibroblasts in the preparation of heterotypic spheroids and a process for the preparation of such heterotypic spheroids. |
Inventor(s): | Mayer; Barbara (Memmingen, DE) |
Assignee: | Sphero Tec GmbH (Martineried, DE) |
Application Number: | 12/643,149 |
Patent Claims: | 1. A process for the preparation of heterogenic fibroblasts comprising the steps of: a) Providing a cell-containing tissue sample; b) Preparing a suspension of
primary cells comprising tissue pieces from the cell-containing tissue sample in a medium; c) Culturing the suspension of primary cells comprising tissue pieces in a vessel coated with a matrix wherein a batch of fibroblast cell nests is generated on
the matrix of the vessel; d) Separating the fibroblast cell nests of step c) from the suspension of primary cells comprising tissue pieces; e) Repeating steps c) to d) at least once whereas the suspension of primary cells comprising tissue pieces of
step d) is re-used within step c) to generate at least one more batch of fibroblast cell nests; wherein the at least two batches of fibroblast, cell nests obtained through steps c) to e) have different types of fibroblasts, and wherein a combination of
the at least two batches of fibroblast cell nests provides heterogenic fibroblasts.
2. The process according to claim 1, wherein the suspension of step b) is also treated with an enzymatic composition containing one or more enzymes selected from the group consisting of proteases, metalloendopeptidases, DNases, hyaloronidases, before culturing according to step c). 3. The process according to claim 2, wherein the enzymatic composition also contains a serum-free medium selected from the group consisting of RPMI, DMEM, F15, MEM, BMEEARL, HAMFSF-12, Leibovitz L-15, McCoys 5A, medium 199, Waymouth medium and HANK-solution. 4. The process according to claim 1, wherein the cell-containing tissue sample is a sample from a tissue selected from the group consisting of a benign tissue, malignant tissue or tumor tissue. 5. The process according to claim 1, wherein the medium is a growth medium. 6. The process according to claim 1, wherein the suspension of primary cells comprising tissue pieces is cultured in the medium at 37.degree. C. for at least 3 days in step c). 7. The process according to claim 6, wherein the suspension of primary cells comprising tissue pieces is cultured in a vessel coated with a gelatine solution. 8. The process according to claim 1, wherein the medium comprises DMEM and FCS or FBS. 9. The process according to claim 1, wherein steps c)-d) are repeated at least 3 times. 10. The process according to claim 1, wherein steps c)-d) are repeated at least 5 times. 11. The process of claim 2, wherein the protease is selected from the group consisting of serine protease, trypsin, dispase, and neutral protease. 12. The process of claim 2, wherein the metalloendopeptidase is selected from the group consisting of collagenase and thermolysin. 13. The process of claim 12, wherein the collagenase is selected from the group consisting of interstitial collagenase and neutrophil collagenase. 14. The process of claim 4, wherein the benign tissue is selected from the group consisting of a gastric tissue, colorectal tissue, liver tissue, lung tissue, mucosal tissue, cerebral tissue, pancreas tissue, hepatic tissue, dermal tissue, prostate or periprostatic tissue, gastric tissue, colonic tissue, ovarial tissue, breast tissue, cervical tissue and glioma tissue. 15. The process of claim 4, wherein the malignant tissue is an inflammatory tissue. 16. The process of claim 4, wherein the tumour tissue is a tissue from a metastatic or primary tumour. 17. The process of claim 4, wherein the tumour tissue is a gastric, pancreas, colorectal, liver, lung, breast, cervical, mucosal, cerebral, hepatic, dermal, colonic, ovarial, sarcoma, prostate or glioma tumor. 18. The process according to claim 5, wherein the growth medium comprises a buffer, a serum, an antibiotic and/or a fungicide. 19. The process according to claim 18, wherein the buffer is phosphate buffered saline (PBS), the serum is foetal calf or bovine serum (FCS or FBS), the antibiotic is Cefazoline and the fungicide is amphotericin B. |
Details for Patent 9,029,148
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Smith & Nephew, Inc. | SANTYL | collagenase | Ointment | 101995 | 06/04/1965 | ⤷ Try a Trial | 2028-12-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.